The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
How can sequential therapy be used in castration-resistant prostate cancer?
The rise of oral chemotherapy and the safety needs of patients
Integration of proton beam therapy with existing modalities
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer